China Universal Asset Management Co. Ltd. Acquires 33,206 Shares of Royalty Pharma plc (NASDAQ:RPRX)

China Universal Asset Management Co. Ltd. increased its stake in Royalty Pharma plc (NASDAQ:RPRX) by 62.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 86,190 shares of the biopharmaceutical company’s stock after acquiring an additional 33,206 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Royalty Pharma were worth $2,438,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc lifted its holdings in Royalty Pharma by 5,215.0% in the 2nd quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,043 shares during the period. Gladius Capital Management LP purchased a new position in Royalty Pharma during the 2nd quarter valued at $32,000. Blue Trust Inc. increased its position in Royalty Pharma by 362.7% during the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 943 shares during the period. Fidelis Capital Partners LLC bought a new position in Royalty Pharma in the 1st quarter worth $46,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Royalty Pharma by 32.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 655 shares during the period. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Trading Up 1.2 %

NASDAQ:RPRX opened at $27.26 on Tuesday. The stock has a market cap of $16.29 billion, a price-to-earnings ratio of 20.34, a PEG ratio of 3.97 and a beta of 0.46. The company has a quick ratio of 9.35, a current ratio of 9.35 and a debt-to-equity ratio of 0.78. The company’s 50 day moving average price is $28.02 and its 200-day moving average price is $27.59. Royalty Pharma plc has a 52 week low of $25.20 and a 52 week high of $31.66.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.01. The firm had revenue of $537.00 million for the quarter, compared to the consensus estimate of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same period in the prior year, the company posted $0.85 earnings per share. On average, equities research analysts forecast that Royalty Pharma plc will post 4.05 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 3.08%. The ex-dividend date is Friday, November 15th. Royalty Pharma’s dividend payout ratio is currently 62.69%.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on RPRX shares. StockNews.com downgraded shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Monday. Citigroup decreased their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research report on Friday. The Goldman Sachs Group lifted their price target on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, Morgan Stanley increased their price objective on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Royalty Pharma has a consensus rating of “Moderate Buy” and an average price target of $41.67.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.